There was a 21% reduction in MACE, an exploratory endpoint, in the obicetrapib group vs placebo after 1 year. Obicetrapib reduced LDL-C in patients with atherosclerotic cardiovascular disease and/or ...

Researchers reveal the structural details of apoB100's interaction with LDL receptors, offering insights into LDL ...

THERE ARE MANY misconceptions about important cardiovascular metrics. Often people think their risk of heart disease and ...

Our top content from the 100th annual American Heart Association (AHA) Scientific Sessions included exclusive expert insights ...

Menarini Group announces positive topline data from pivotal phase 3 BROADWAY & TANDEM trials of Obicetrapib and FDC Obicetrapib with Ezetimibe 10 mg: Florence, Italy Wednesday, De ...

A recent study confirms that unprocessed beef can be part of a heart-healthy diet without raising cardiovascular disease risk ...

The topline results from the Phase III trial found the treatment to be well tolerated with a reduction in low-density ...

A very, very interesting result was about a 57% lowering of lipoprotein A. This is all on top of increasing HDL. So again, a very pleiotropic compound, but I like that it also has that apo B benefit.

Finally, all statistical models included apo B to account for differences in the proatherogenic lipoprotein fraction. In the IDEAL study, we observed that plasma levels of HDL-C were indeed ...

high-density lipoprotein cholesterol (HDL-C), triglycerides, non-HDL-C, apolipoprotein (apo) A, apo B, and very low-density lipoprotein cholesterol (VLDL-C). Unprocessed beef contains more cholesterol ...

using an intact lipoprotein(a) assay, and 40.4, 70.0, and 68.9 percent, respectively, using an apolipoprotein(a)-based assay. Dose-dependent reductions in apolipoprotein B were seen for 8.9 ...